Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K1XK
|
|||
| Former ID |
DAP000728
|
|||
| Drug Name |
Hydralazine
|
|||
| Synonyms |
Apresolin; Apresoline; Apressin; Apressoline; Aprezolin; HLZ; Hidral; Hidralazin; Hidralazina; Hipoftalin; Hydralazin; Hydralazinum; Hydrallazin; Hydrallazine; Hydrazinophthalazine; Hypophthalin; Idralazina; Hidralazina [Spanish]; Idralazina [DCIT]; Idralazina [Italian]; BA 5968; C 5968; Ciba 5968; Praparat 5968; Apresoline (TN); Apressin (pharmaceutical); C-5068; C-5968; Hidral (TN); Hidralazina [INN-Spanish]; Hydralazine (INN); Hydralazine [INN:BAN]; Hydralazinum [INN-Latin]; Hydrazone 1(2H)-phthalazinone; Phthalazin-1-ylhydrazine; [2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride; (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone, hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H8N4
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C=NN=C2NN
|
|||
| InChI |
1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
|
|||
| InChIKey |
RPTUSVTUFVMDQK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 86-54-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9252, 418631, 5137562, 6166136, 7979543, 8152294, 10537093, 11111261, 11111262, 11335292, 11360531, 11363769, 11366331, 11368893, 11371450, 11373488, 11377055, 11449000, 11461503, 11466197, 11467317, 11484713, 11485694, 11488785, 11490271, 11491820, 11494689, 15171016, 29203528, 29222762, 46507533, 47216638, 47290993, 47440105, 47478169, 47515168, 47662118, 48184848, 48416088, 50010164, 50111090, 53790673, 56313050, 56313323, 56313748, 57321912, 74312335, 77248068, 85789545, 87692111
|
|||
| ChEBI ID |
CHEBI:5775
|
|||
| ADReCS Drug ID | BADD_D01081 ; BADD_D01082 | |||
| SuperDrug ATC ID |
C02DB02
|
|||
| SuperDrug CAS ID |
cas=000086544
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Membrane copper amine oxidase (AOC3) | Target Info | Modulator | [3] |
| BioCyc | Phenylethylamine degradation I | |||
| Spermine and spermidine degradation I | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| beta-Alanine metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Phenylethylamine degradation | |||
| Pathwhiz Pathway | Beta-Alanine Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7326). | |||
| REF 2 | Drug information of Hydralazine, 2008. eduDrugs. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.